Your AI-Trained Oncology Knowledge Connection!

Updates in HER2+ Early and Metastatic Breast Cancer : Episode 13

Video

March 6, 2023

Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

Author(s):

Joyce O’Shaughnessy, MD,Virginia Borges, MD

The panel discusses the management of patients with HER2+ mBC with asymptomatic brain mets and shares their thoughts on the use of surveillance brain MRI in this setting.

EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer

EP: 3.De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

EP: 4.Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

EP: 5.Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP: 6.Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

EP: 7.Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP: 8.Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

EP: 9.Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

EP: 10.HER2+ mBC: First-Line Treatment Regimens

EP: 11.Second-Line Treatment of HER2+ mBC and Recent Data Updates

EP: 12.Options for Third- and Further-Line Treatment of HER2+ mBC

Now Viewing

EP: 13.Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP: 14.Emerging Data and Investigational Agents in HER2+ mBC

EP: 15.Unmet Needs and the Future of HER2+ Breast Cancer Treatment

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity

Latest Conference Coverage

Hematologists Highlight Notable Insights From the 2025 EHA Congress

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

View More Latest Conference Coverage

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Privacy

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP: 1.Incidence and Typical Prognosis of HER2+ Early Breast Cancer

EP: 2.Neoadjuvant Treatment of HER2+ Early Breast Cancer

EP: 3.De-Escalation Approaches in Patients with HER2+ Early Breast Cancer

EP: 4.Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer

EP: 5.Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer

EP: 6.Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)

EP: 7.Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer

EP: 8.Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer

EP: 9.Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022

EP: 10.HER2+ mBC: First-Line Treatment Regimens

EP: 11.Second-Line Treatment of HER2+ mBC and Recent Data Updates

EP: 12.Options for Third- and Further-Line Treatment of HER2+ mBC

EP: 13.Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC

EP: 14.Emerging Data and Investigational Agents in HER2+ mBC

EP: 15.Unmet Needs and the Future of HER2+ Breast Cancer Treatment

Newsletter

Latest CME

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Latest Conference Coverage